


EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA



C. Alarcón-Payer¹, J.E. Martínez-De la Plata¹, S. Cano Domínguez¹, M.E. Clavero Sánchez², R. Ríos Tamayo², M. Jurado Chacón², A. Jiménez Morales¹

Servicio de Farmacia. Hospital Universitario Virgen de las Nieves. Granada¹

Servicio de Hematología y Hemoterapia. Hospital Universitario Virgen de las Nieves. Granada²


e-mail: carolina.alarcon.sspa@juntadeandalucia.es



4CPS-103

PURPOSE

To evaluate the health outcomes of daratumumab in monotherapy in the treatment of adult patients with relapsed refractory multiple myeloma (RRMM), who have previously received a proteasome inhibitor and an immunomodulatory agent and who have experienced disease progression in the last treatment.



MATERIAL AND METHODS

Prospective observational study conducted over a period of 2 years in a third level hospital. Eleven patients diagnosed with RRMM have been analyzed. To evaluate the measurement of health outcomes, the following variables were measured: age, sex, number of previous lines, daratumumab cycles received, progression-free survival (PFS) and adverse reactions.

RESULTS

MEDIDA DE RESULTADOS EN SALUD

Eleven RRMM cases were analyzed (80%: men; 20%: women): The mean age was 63 years.

50% → Daratumumab in monotherapy in 3rd line


30% → Daratumumab in monotherapy in 4rd line

20% → Daratumumab in monotherapy in 6rd and 7rd line

The mean number of daratumab cycles → 7 except for one patient who has now completed cycle 20

The median PFS (months) → 4

Adverse reactions → nausea and vomiting (20%)



CONCLUSION

- Health outcomes of daratumumab in monotherapy for the treatment of patients with RRMM are similar to those published in the combined trial gene 501 and SIRIUS.
- According to recent publications, daratumumab is likely to be more effective in combination with other drugs.
- Daratumumab is well tolerated in most patients and is therefore considered a safe treatment.